Abstract
Neuroblastoma is a heterogeneous tumour and its effective clinical management is dependent on accurate prognostic evaluation. In approximately 25% of patients amplification of the MYCN oncogene is known to be associated with a poor outcome. In order to identify additional molecular markers with prognostic potential in non-MYCN-amplified neuroblastomas, we looked for a correlation between clinical outcome and loss of heterozygosity (LOH) on four chromosomes that frequently show alteration in neuroblastoma (chromosomes 3, 4, 11 and 14). Chromosome 11q loss (with frequent parallel loss of chromosomes 3p, 4p and/or 14q) was found exclusively in tumours without MYCN amplification and was significantly associated with poor event-free survival. The 2-year event-free survival rate for 11q LOH cases was 30%, compared to 34% for MYCN-amplified cases and 100% for cases without these abnormalities. While 11q LOH was associated predominantly with advanced-stage disease, 2 cases with low-stage disease and 11q LOH both suffered relapses. We conclude that chromosome 11q loss defines a biologically distinct group of tumours without MYCN amplification that appear to have potential for aggressive metastatic growth. Thus this genetic alteration may be an important new prognostic marker in neuroblastoma. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson ADJ, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, Laureys G and Speleman F (1999) Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Eng J Med 340: 1954–1961
Brinkschmidt C, Poremba C, Christiansen H, Simon R, Schafer KL, Terpe HJ, Lampert F, Boecker W and Dockhorn-Dworniczak B (1998) Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas. Br J Cancer 77: 2223–2229
Brodeur GM (1995) Molecular Basis For Heterogeneity in Human Neuroblastomas. Eur J Cancer 31A: 505–510
Brodeur GM, Maris JM, Yamashiro DJ, Hogarty MD and White PS (1997) Biology and genetics of human neuroblastomas. J Ped Hematol/Oncol 19: 93–101
Brodeur GM, Pritchard J, Berthold F, Carlsen NLT, Castel V, Castleberry RP, de Bernardi B, Evans AE, Favrot M, Hedborg F, Kaneko M, Kemshead J, Lampert F, Lee REJ, Look AT, Pearson ADJ, Philip T, Roald B, Sawada T, Seeger RC, Tsuchida Y and Voute PA (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 11: 1466–1477
Caron H (1995) Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 24: 215–221
Caron H, Peter M, van Sluis P, Speleman F, de Kraker J, Laureys G, Michon J, Brugieres L, Voute PA, Westerveld A, Slater R, Delattre O and Versteeg R (1995) Evidence for two tumour suppressor loci on chromosomal bands 1 p35–36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. Hum Mol Genet 4: 535–539
Caron H, vanSluis P, Buschman R, doTanque RP, Maes P, Beks L, deKraker J, Voute P, Vergnaud G, Westerveld A, Slater R and Versteeg R (1996) Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locus. Hum Genet 97: 834–837
Chalifa-Caspi V, Prilusky J and Lancet D (1998) The Unified Database. http://bioinformatics.weizmann.ac.il/udb
Cheng NC, VanRoy N, Chan A, Beitsma M, Westerveld A, Speleman F and Versteeg R (1995) Deletion mapping in neuroblastoma cell-lines suggests 2 distinct tumor-suppressor genes in the 1p35–36-region, only one of which is associated with N-myc amplification. Oncogene 10: 291–297
Ejeskar K, Aburatani H, Abrahamsson J and Kogner P Martinsson (1998) Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. Br J Cancer 77: 1787–1791
Fong C-T, Dracopoli NC, White PS, Merrill PT, Griffith RC, Housman DE and Brodeur GM (1989) Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: Correlation with N-myc amplification. Proc Natl Acad Sci USA 86: 3753–3757
Fong C-T, White PS, Peterson K, Sapienza C, Cavenee WK, Kern SE, Vogelstein B, Cantor AB, Look AT and Brodeur GM (1992) Loss of heterozygosity for chromosome 1 or 14 defines subsets of advanced stage neuroblastomas. Cancer Res 52: 1780–1785
Gehring M, Berthold F, Edler L, Schwab M and Ambler LC (1995) The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 55: 5366–5369
Gryfe R, Swallow C, Bapat B, Redston M, Gallinger S and Couture J (1997) Molecular biology of colorectal cancer. Curr Probl Cancer 21: 238–301
Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, Gerbing R, Matthay KK, Seeger RC, Brodeur GM and Maris JM (1999) Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 18: 4948–4957
Guo C, White PS, Hogarty MD, Brodeur GM, Gerbing R, Stram DO and Maris JM (2000) Deletion of 11q23 is a frequent event in the evolution of MYCN single copy high risk neuroblastomas. Med Ped Oncol 35: 544–546
Hoshi M, Otagiri N, Shiwaku H, Asakawa S, Shumizu N, Kaneko Y, Ohi R, Hayashi Y and Horii A (2000) Detailed deletion mapping of chromosome band 14q32 in human neuroblastoma defines a 1.1 Mb region of common allelic loss. Br J Cancer 82: 1801–1807
Kerbl R, Urban CE, Lackner H, Hofler G, Ambros IM, Ratschek M and Ambros PF (1996) Connatal localized neuroblastoma. Cancer 77: 1395–1401
Lastowska M, Nacheva E, McGuckin A, Curtis A, Grace C, Pearson A and Bown N (1997) Comparative genomic hybridization study of primary neuroblastoma tumours. Genes Chromosomes Cancer 18: 162–169
Lastowska M, Cullinane C, Variend S, Cotterill S, Bown N, O'Neill S, Mazzocco K, Roberts P, Nicholson J, Ellershaw C, Pearson A and Jackson M (2000) Genetic and histopathological analysis of neuroblastoma tumours. Med Ped Oncol 35: 204
Maris J, White P, Beltinger C, Sulman E, Castleberry R, Shuster J, Look A and Brodeur G (1995) Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 55: 4664–4669
Mora J, Cheung N, Kushner B, LaQuaglia M, Kramer K, Fazzari M, Heller G, LS C and Gerald W (2000) Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome are 1p. J Mol Diag 2: 37–46
Plantaz D, Mohapatra G, Matthay KK, Pellarin M, Seeger RC and Feuerstein BG (1997) Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol 150: 81–89
Powell JE, Esteve J, Mann JR, Parker L, Frappaz D, Michaelis J, Kerbl R, Mutz ID and Stiller CA (1998) Neuroblastoma in Europe: differences in the pattern of disease in the UK. Lancet 352: 682–687
Schleiermacher G, Delattre O, Peter M, Mosseri V, Delonlay P, Vielh P, Thomas G, Zucker JM, Magdelenat H and Michon J (1996) Clinical relevance of loss of heterozygosity of the short arm of chromosome 1 in neuroblastoma: a single institution study. Int J Cancer 69: 73–78
Schleiermacher G, Peter M, Michon J, Hugot JP, Vielh P, Zucker JM, Magdelenat H, Thomas G and Delattre O (1994) Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma. Genes Chromosomes Cancer 10: 275–281
Srivatsan ES, Ying KL and Seeger RC (1993) Deletion of chromosome 11 and 14q sequences in neuroblastoma. Genes Chromosomes Cancer 7: 32–37
Suzuki T, Yokota J, Mugishima H, Okabe I, Ookuni M, Sugimura T and Terada M (1989) Frequent loss of heterozygosity on chromosome 14q in neuroblastoma. Cancer Res 49: 1095–1098
Takayama H, Suzuki T, Mugishima H, Fujisawa T, Ookuni M, Schwab M, Gehring M, Nakamura Y, Sugimura T, Terada M and Yokota J (1992) Deletion mapping of chromosome-14q and chromosome-1p in human neuroblastoma. Oncogene 7: 1185–1189
Takeda O, Homma C, Maseli N, Sakurai M, Kanda N, Schwab M, Nakamura Y and Kaneko Y (1994) There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes chromosome Cancer 10: 30–39
Thompson PM, Kyemba SK, Jensen SJ, Guo C, Maris JM, Brodeur GM, Stram DO, Matthay KK, Seger RC and White PS (2001) Loss of heterozygosity (LOH) from chromosome 14q in neuroblastoma. Med Ped Oncol
Theobald M, Christiansen H, Schmidt A, Melekian B, Wolkewitz N, Christiansen NM, Brinkschmidt C, Berthold F and Lampert F (1999) Sublocalization of putative tumor suppressor gene loci on chromosome arm 14q in neuroblastoma. Genes Chromosomes Cancer 26: 40–46
Vandesompele J, Van Roy N, Van Gele M, Laureys G, Ambros P, Heimann P, Devalck C, Schuuring E, Brock P, Otten J, Gyselinck J, De Paepe A and Speleman F (1998) Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer 23: 141–152
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Luttikhuis, M., Powell, J., Rees, S. et al. Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis. Br J Cancer 85, 531–537 (2001). https://doi.org/10.1054/bjoc.2001.1960
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1960
Keywords
This article is cited by
-
The emerging role of the KCTD proteins in cancer
Cell Communication and Signaling (2021)
-
Systematic computational identification of prognostic cytogenetic markers in neuroblastoma
BMC Medical Genomics (2019)
-
11q deletion in neuroblastoma: a review of biological and clinical implications
Molecular Cancer (2017)
-
The Role of Id2 Protein in Neuroblatoma in Children
Pathology & Oncology Research (2015)
-
The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis
Pediatric Surgery International (2013)